Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia

 Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia

Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia

Shots:

  • The collaboration offers a compassionate access program to make the combination therapy of Veyonda & 7Lu-PSMA available to the patients suffering from mCRPC, being treated with theranostics in Australia
  • The combination regimen is currently being evaluated in clinical studies in patients with advanced mCRPC, demonstrating improvement in response rate with mOS (17.1mos.) and a reduction in pain following disease progression
  • Veyonda (bid for 10 days) is a suppository dosage form of idronoxil and inhibitor of S1P and enhances the effect of Lutetium-PSMA (Lu-PSMA) in men with advanced PC

Click here ­to­ read full press release/ article | Ref: Noxopharm | Image: Noxopharm

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post